Ameet Dravid

568 total citations · 1 hit paper
21 papers, 343 citations indexed

About

Ameet Dravid is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Ameet Dravid has authored 21 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 15 papers in Virology and 7 papers in Emergency Medicine. Recurrent topics in Ameet Dravid's work include HIV Research and Treatment (15 papers), HIV/AIDS Research and Interventions (13 papers) and HIV/AIDS drug development and treatment (7 papers). Ameet Dravid is often cited by papers focused on HIV Research and Treatment (15 papers), HIV/AIDS Research and Interventions (13 papers) and HIV/AIDS drug development and treatment (7 papers). Ameet Dravid collaborates with scholars based in India, United States and Italy. Ameet Dravid's co-authors include Sanjay Pujari, Eknath Naik, Kaley Tash, Jeffrey P. Nadler, John T. Sinnott, Atul Patel, Uma Mahajan, Ketan Patel, Jagdish K. Patel and Sachin D. Kore and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and Emerging infectious diseases.

In The Last Decade

Ameet Dravid

18 papers receiving 332 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cognitive impairment in people living with HIV: consensus recommendations for a new approach

2023 66 citations Sam Nightingale, Beau M. Ances et al. Nature Reviews Neurology profile →

Peers

Countries citing papers authored by Ameet Dravid

Since Specialization

Citations

This map shows the geographic impact of Ameet Dravid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ameet Dravid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ameet Dravid more than expected).

Fields of papers citing papers by Ameet Dravid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ameet Dravid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ameet Dravid. The network helps show where Ameet Dravid may publish in the future.

Co-authorship network of co-authors of Ameet Dravid

This figure shows the co-authorship network connecting the top 25 collaborators of Ameet Dravid. A scholar is included among the top collaborators of Ameet Dravid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ameet Dravid. Ameet Dravid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation 2024 ·Journal of Clinical Investigation ·Laura P. Kincer, Ameet Dravid, Mattia Trunfio, Andrea Calcagno, Shuntai Zhou, (unknown), Serena Spudich, Magnus Gisslén, Richard W. Price, Paola Cinque, Sarah Joseph	6
2	Changes in cerebrospinal fluid proteins across the spectrum of untreated and treated chronic HIV-1 infection 2024 ·PLoS Pathogens ·Zicheng Hu, Paola Cinque, Ameet Dravid, Lars Hagberg, Aylin Yilmaz, Henrik Zetterberg, Dietmar Fuchs, Johanna M. Gostner, Kaj Blennow, Serena Spudich, Laura P. Kincer, Shuntai Zhou, Sarah Joseph, Ronald Swanstrom, Richard W. Price, Magnus Gisslén	0
3	Reply to ‘Cognitive criteria in HIV: greater consensus is needed’ 2024 ·Nature Reviews Neurology ·Sam Nightingale, Paola Cinque, Ameet Dravid, Anna J. Dreyer, Magnus Gisslén, John A. Joska, Judith Kwasa, Ana‐Claire Meyer, (unknown), Noeline Nakasujja, Richard Pebody, Anton Pozniak, Richard W. Price, Deanna Saylor, Kevin G. F. Thomas, Jonathan Underwood, Jaime H. Vera, Alan Winston	2
4	Viral co-infection, autoimmunity, and CSF HIV antibody profiles in HIV central nervous system escape 2023 ·Journal of Neuroimmunology ·Isobel A. Hawes, Bonny D. Alvarenga, (unknown), Anne E. Wapniarski, Ravi Dandekar, Christopher M. Bartley, Gavin M. Sowa, Joseph L. DeRisi, Paola Cinque, Ameet Dravid, Samuel J. Pleasure, Magnus Gisslén, Richard W. Price, Michael R. Wilson	5
5	Cognitive impairment in people living with HIV: consensus recommendations for a new approach breakdown → 2023 ·Nature Reviews Neurology ·Sam Nightingale, Beau M. Ances, Paola Cinque, Ameet Dravid, Anna J. Dreyer, Magnus Gisslén, John A. Joska, Judith Kwasa, Ana‐Claire Meyer, (unknown), Noeline Nakasujja, Richard Pebody, Anton Pozniak, Richard W. Price, Christopher Sandford, Deanna Saylor, Kevin G. F. Thomas, Jonathan Underwood, Jaime H. Vera, Alan Winston	66
6	A new approach to cognitive impairment in people with HIV 2022 ·The Lancet HIV ·Sam Nightingale, Paola Cinque, John A. Joska, Richard W. Price, Jonathan Underwood, Beau M. Ances, Ameet Dravid, Anna J. Dreyer, Magnus Gisslén, Judith Kwasa, Ana-Claire Meyer, (unknown), Noeline Nakasujja, Richard Pebody, Anton Pozniak, Christopher Sandford, Deanna Saylor, Kevin G. F. Thomas, Jaime H. Vera, Alan Winston	2
7	A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1 2022 ·PubMed ·Ameet Dravid, (unknown), (unknown), John Ramapuram, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Surabhi Madan, (unknown), (unknown)	3
8	Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial 2022 ·Medicine ·Ameet Dravid, (unknown), (unknown), (unknown), John Ramapuram, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
9	Cerebral Venous Sinus Thrombosis (CVST) as a Complication of SARS-COV2 Infection 2022 ·(unknown), (unknown), Rahul Kulkarni, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sujit Jagtap, Ameet Dravid, (unknown), Sameer Jog, (unknown), Sarita Gajbhiye Meshram	0
10	Online Registry of COVID-19–Associated Mucormycosis Cases, India, 2021 2021 ·Emerging infectious diseases ·Shitij Arora, Vagish Hemmige, Charuta Mandke, (unknown), Sumit Kumar Rawat, Ameet Dravid, (unknown), (unknown), Sunit Jariwala, Yoram A. Puius, (unknown)	8
11	Neurological issues during severe COVID-19 in a tertiary level hospital in Western India 2021 ·Neuroscience Letters ·Ameet Dravid, (unknown), (unknown)	5
12	Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India 2020 ·HIV Medicine ·Ameet Dravid, (unknown), (unknown), (unknown), Uma Mahajan, (unknown), (unknown), (unknown), (unknown), (unknown)	3
13	Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India 2019 ·BMC Infectious Diseases ·Ameet Dravid, (unknown), (unknown), (unknown), Uma Mahajan, (unknown), (unknown), (unknown), Sachin D. Kore, (unknown), (unknown)	35
14	Strongyloidosis Hyperinfection Syndrome in an HIV-Infected Patient: A Rare Manifestation of Immune Reconstitution Inflammatory Syndrome 2018 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Divya Patel, (unknown), (unknown), (unknown), (unknown), Ameet Dravid	9
15	Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India 2018 ·Medicine ·Ameet Dravid, (unknown), (unknown), (unknown), Uma Mahajan, Sachin D. Kore, (unknown), (unknown), R S Wadia	23
16	Prevalence of low bone mineral density among HIV patients on long‐term suppressive antiretroviral therapy in resource limited setting of western India 2014 ·Journal of the International AIDS Society ·Ameet Dravid, (unknown), (unknown), (unknown)	12
17	Tenofovir‐induced acute kidney injury in HIV‐infected patients in western India: a resource limited setting perspective 2012 ·Journal of the International AIDS Society ·(unknown), Nikhil C. Munshi, (unknown), Ameet Dravid	4
18	Effectiveness and Safety of Generic Fixed‐Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV‐1‐Infected Patients in Western India 2008 ·Journal of the International AIDS Society ·Sanjay Pujari, Ameet Dravid, Nikhil Gupte, (unknown), (unknown)	14
19	Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. 2005 ·PubMed ·Sanjay Pujari, Ameet Dravid, Eknath Naik, (unknown), Kaley Tash, Jeffrey P. Nadler, John T. Sinnott	86
20	Effectiveness of Generic Fixed-Dose Combinations of Highly Active Antiretroviral Therapy for Treatment of HIV Infection in India 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Sanjay Pujari, Atul Patel, Eknath Naik, Ketan Patel, Ameet Dravid, Jagdish K. Patel, (unknown), (unknown)	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact